This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos. For additional information please visit NEWSCENTRE.
Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study
New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers
First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation
Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment- For Non-US/Non-UK/Non-Canadian Media
Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada- For Non-US/Non-UK Media